A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

If you’ve been hearing a lot about GLP-1 receptor agonists like semaglutide, you’re not alone. The popularity of semaglutide, the active ingredient in Ozempic and Wegovy, has skyrocketed in ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Wegovy's sales fell slightly short of ... after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Wegovy and Zepbound are approved for weight ... In a separate study, participants on Ozempic lowered their A1c by 2.1% on a 2-mg dose. Based on these results, Ozempic may be more effective in ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market ... 2.4 mg, which is currently the highest dose of the drug marketed under the Wegovy brand for ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...